Osteopetrosis: the follow-up of the disease in a patient who underwent hematopoietic stem cell transplantation at the age of 27 years
Victor M. Zhilyaev,
Svetlana D. Arapova,
Elizaveta O. Mamedova,
Natalya V. Tarbaeva,
Zhanna E. Belaya https://doi.org/10.14341/osteo12434
Abstract
Osteopetrosis is a rare hereditary disease that develops as a result of genetic mutations leading to impaired development and function of osteoclasts. There are several forms of osteopetrosis that differ in the type of inheritance (autosomal recessive, autosomal dominant and intermediate) and the severity of symptoms. The main clinical manifestations of the disease are frequent pathological fractures, anemia, thrombocytopenia, infectious complications, compression of the cranial nerves and impaired function. With timely diagnosis and successful hematopoietic stem cell transplantation (HSCT), the prognosis is favorable. In the vast majority of cases, transplantation is performed in the first 10 months of life. The literature describes only 12 patients with osteopetrosis who underwent HSCT over the age of 5 years. The article presents a clinical case of osteopetrosis due to a mutation in the CA2 gene (Chr8: 86389420C> G, p.Y193X) in a 30-year-old patient who underwent THSC at the age of 27.
About the Authors
Victor M. Zhilyaev
Endocrinology Research Centre
MD
MD
Svetlana D. Arapova
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
Elizaveta O. Mamedova
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
Natalya V. Tarbaeva
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
Zhanna E. Belaya
Endocrinology Research Centre
Russian Federation
Russian Federation
MD, PhD
References
1. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N. Engl. J. Med. 2004;351(27):2839-2849. doi: https://doi.org/10.1056/NEJMra040952.
2. Albers-Schönberg HE. Röntgenbilder einer seltenen Knockenerkrankung. Munch Med Wochenschr. 1904;(51):365-368.
3. Kovanlikaya A, Loro ML, Gilsanz V. Pathogenesis of osteosclerosis in autosomal dominant osteopetrosis. Am. J. Roentgenol. 1997;168(4):929-932. doi: https://doi.org/10.2214/ajr.168.4.9124142.
4. Arruda M, Coelho MCA, Moraes AB, et al. Bone Mineral Density and Microarchitecture in Patients With Autosomal Dominant Osteopetrosis: A Report of Two Cases. J. Bone Miner. Res. 2016;31(3):657-662. doi: https://doi.org/10.1002/jbmr.2715.
5. Wu CC, Econs MJ, DiMeglio LA, et al. Diagnosis and Management of Osteopetrosis: Consensus Guidelines From the Osteopetrosis Working Group. J. Clin. Endocr. Metab. 2017;102(9):3111-3123. doi: https://doi.org/10.1210/jc.2017-01127.
6. Campos-Xavier AB, Casanova J-L, Doumaz Y, et al. Intrafamilial phenotypic variability of osteopetrosis due to chloride channel 7 (CLCN7) mutations. Am. J. Med. Genet. A. 2005;133A(2):216-218. doi: https://doi.org/10.1002/ajmg.a.30490.
7. Sobacchi C, Schulz A, Coxon FP, et al. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nature Reviews Endocrinology. 2013;9(9):522-536. doi: https://doi.org/10.1038/nrendo.2013.137.
8. Bliznetz EA, Tverskaya SM, Zinchenko RA, et al. Genetic analysis of autosomal recessive osteopetrosis in Chuvashiya: the unique splice site mutation in TCIRG1 gene spread by the founder effect. Eur. J. Hum. Genet. 2009;17(5):664-672. doi: https://doi.org/10.1038/ejhg.2008.234.
9. Johnston CC, Jr., Lavy N, Lord T, et al. Osteopetrosis. A clinical, genetic, metabolic, and morphologic study of the dominantly inherited, benign form. Medicine (Baltimore). 1968;47(2):149-167.
10. Bollerslev J, Andersen PE, Jr. Radiological, biochemical and hereditary evidence of two types of autosomal dominant osteopetrosis. Bone. 1988;9(1):7-13. doi: https://doi. org/10.1016/8756-3282(88)90021-x.
11. Al-Tamimi YZ, Tyagi AK, Chumas PD, Crimmins DW. Patients with autosomal-recessive osteopetrosis presenting with hydrocephalus and hindbrain posterior fossa crowding. J. Neurosurg. Pediatr. 2008;1(1):103-106. doi: https://doi.org/10.3171/ped-08/01/103.
12. Bosley TM, Salih MA, Alorainy IA, et al. The neurology of carbonic anhydrase type II deficiency syndrome. Brain. 2011;134(12):3502-3515. doi: https://doi.org/10.1093/brain/awr302.
13. Ismail EAR, Abul Saad S, Sabry MA. Nephrocalcinosis and urolithiasis in carbonic anhydrase II deficiency syndrome. Eur. J. Pediatr. 1997;156(12):957-962. doi: https://doi.org/10.1007/s004310050751.
14. Totan M, Albayrak D. Osteopetrosis — improvement of hematologic findings with age. The Indian Journal of Pediatrics. 1999;66(5):809-812. doi: https://doi.org/10.1007/bf02726275.
15. Grodum E, Gram J, Brixen K, Bollerslev J. Autosomal dominant osteopetrosis: bone mineral measurements of the entire skeleton of adults in two different subtypes. Bone. 1995;16(4):431-434. doi: https://doi.org/10.1016/8756-3282(95)90188-4.
16. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos. Int. 2010;21(7):1151-1154. doi: https://doi.org/10.1007/s00198-010-1285-3.
17. Orchard PJ, Fasth AL, Le Rademacher J, et al. Hematopoietic stem cell transplantation for infantile osteopetrosis. Blood. 2015;126(2):270-276. doi: https://doi.org/10.1182/blood-2015-01-625541.
18. Martinez C, Polgreen LE, DeFor TE, et al. Characterization and management of hypercalcemia following transplantation for osteopetrosis. Bone Marrow Transplant. 2009;45(5):939-944. doi: https://doi.org/10.1038/bmt.2009.277.
19. Stepensky P, Grisariu S, Avni B, et al. Stem cell transplantation for osteopetrosis in patients beyond the age of 5 years. Blood Advances. 2019;3(6):862-868. doi: https://doi.org/10.1182/bloodadvances.2018025890.
20. Behfar M, Dehghani SS, Hosseini AS, et al. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis. Pediatr. Transplant. 2015;19(4):422-427. doi: https://doi.org/10.1111/petr.12476.
21. Shadur B, Zaidman I, NaserEddin A, et al. Successful hematopoietic stem cell transplantation for osteopetrosis using reduced intensity conditioning. Pediatr. Blood Cancer. 2018;65(6):e27010. doi: https://doi.org/10.1002/pbc.27010.
22. Schulz AS, Moshous D, Steward CG, Villa A, Sobacchi C. Osteopetrosis. Consensus Guidelines for Diagnosis, Therapy and Follow-Up (2015). Available online at: https://Esid.Org/.2015.654.
Supplementary files
Review
For citations:
Zhilyaev V.M., Arapova S.D., Mamedova E.O., Tarbaeva N.V., Belaya Zh.E. Osteopetrosis: the follow-up of the disease in a patient who underwent hematopoietic stem cell transplantation at the age of 27 years. Osteoporosis and Bone Diseases. 2020;23(1):14-19. (In Russ.) https://doi.org/10.14341/osteo12434
Views:
751
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
